COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID

Diseases of the Esophagus

Volumn 21, Issue 1, 2008, Pages 9-14

  Liu, X ^a   Li, P ^a   Zhang, Shu Tian ^a   You, H ^a   Jia, J D ^a   Yu, Z L ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Esophageal squamous cell carcinoma; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ASPIRIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES;

EID: 38049119760     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00697.x     Document Type: Article

References (26)

1. Ratnasinghe D, Tangrea J, Roth M J et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus: An immunohistochemical survey. Anticancer Res 1999; 19: 171-4.
2. Shamma A, Yamamoto H, Doki Y et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229-38.
3. Kawabe A, Shimada Y, Uchida S et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002; 62: 46-54.
4. Kase S, Osaki M, Honjo S et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma. Pathobiology 2004; 71: 84-92.
5. Yu H P, Liu L, Shi L Y et al. Expression of cyclooxygenase-2 in esophageal squamous cell carcinogenesis. Zhonghua Yu Fang Yi Xue Za Zhi 2004; 38: 22-5.
6. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J 2003; 17: 1986-95.
7. Sheu B S, Yang H B, Sheu S M et al. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003; 9: 5245-51.
8. Kase S, Osaki M, Honjo S et al. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch 2003; 442: 129-35.
9. Nishihara H, Kizaka-Kondoh S, Insel P A et al. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 2003; 100: 8921-6.
10. Chu J, Lloyd F L, Trifan O C et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003; 2: 1-7.
11. Lim S C. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep 2003; 10: 1241-9.
12. Li H X, Chang X M, Song Z J et al. Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma. World J Gastroenterol 2003; 9: 674-7.
13. Zhang W, Wang L, Chang A et al. Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China. Cancer Detect Prev 2003; 27: 243-9.
14. Yu H P, Xu S Q, Liu L et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett 2003; 198: 193-201.
15. Kuo K T, Chow K C, Wu Y C et al. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 2003; 76: 909-14.
16. Yao M, Kargman S, Lam E C et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-92.
17. Yasumaru M, Tsuji S, Tsujii M et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 2003; 63: 6726-34.
18. Williams J L, Nath N, Chen J et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: Implications for chemoprevention. Cancer Res 2003; 63: 7613-18.
19. Hong S K, Gul Y A, Ithnin H et al. Expression of beta-catenin, COX-2 and iNOS in colorectal cancer: Relevance of COX-2 and iNOS inhibitors for treatment in Malaysia. Asian J Surg 2004; 27: 10-17.
20. De Leng W W, Westerman A M, Weterman M A et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003; 9: 3065-72.
21. Vona-Davis L, Riggs D R, Jackson B J et al. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro. J Surg Res 2004; 119: 143-8.
22. Yu H P, Shi L Y, Lu W H et al. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004; 19: 638-42.
23. Kase S, Osaki M, Honjo S et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004; 23: 301-7.
24. Swamy M V, Herzog C R, Rao C V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003; 63: 5239-42.
25. Lang S, Lauffer L, Clausen C et al. Impaired monocyte function in cancer patients: Restoration with a cyclooxygenase-2 inhibitor. FASEB J 2003; 17: 286-8.
26. Sharma S, Stolina M, Yang S C et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003; 9: 961-8.